Christopher Hite's most recent trade in Royalty Pharma plc - Ordinary Shares - Class A was a trade of 97,446 Class A Ordinary Shares done at an average price of $56.5 . Disclosure was reported to the exchange on June 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Chairman, Partnering | Sale of securities on an exchange or to another person at price $ 56.50 per share. | 30 Jun 2026 | 97,446 | 461,953 | - | 56.5 | 5,505,972 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Chairman, Partnering | Sale of securities on an exchange or to another person at price $ 56.44 per share. | 30 Jun 2026 | 29,400 | 40,600 | - | 56.4 | 1,659,404 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Chairman, Partnering | Sale of securities on an exchange or to another person at price $ 57.10 per share. | 30 Jun 2026 | 2,554 | 459,399 | - | 57.1 | 145,841 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Chairman, Partnering | Sale of securities on an exchange or to another person at price $ 57.09 per share. | 30 Jun 2026 | 600 | 40,000 | - | 57.1 | 34,254 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Chairman, Partnering | Sale of securities on an exchange or to another person at price $ 54.47 per share. | 23 Jun 2026 | 117,592 | 559,399 | - | 54.5 | 6,405,777 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Chairman, Partnering | Sale of securities on an exchange or to another person at price $ 54.11 per share. | 23 Jun 2026 | 32,408 | 676,991 | - | 54.1 | 1,753,500 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2026 | 24,263 | 709,399 | - | 0 | Class A Ordinary Shares | |
| Kailera Therapeutics Inc | Christopher Hite | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2026 | 38,300 | 38,300 | - | - | Stock Option (right to buy) | |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2026 | 26,626 | 685,136 | - | 0 | Class A Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Nov 2025 | 6,168 | 658,510 | - | 0 | Class A Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2025 | 3,696 | 652,342 | - | 0 | Class A Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 1,238,789 | 1,238,789 | - | - | Class E Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 48,646 | 648,646 | - | 0 | Class A Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Vice Chairman | 14 Feb 2025 | 300,000 | 600,000 | - | 0 | Class A Ordinary Shares | ||
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Vice Chairman | 14 Feb 2025 | 30,000 | 86,641 | - | - | LP interests in RPI US Partners 2019, LP | ||
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Vice Chairman | 13 May 2024 | 300,000 | 370,000 | - | 0 | Class A Ordinary Shares | ||
| Royalty Pharma PLC (Class A) | Christopher Hite | EVP & Vice Chairman | 13 May 2024 | 30,000 | 541 | - | - | LP interests in RPI US Partners 2019, LP |